Clinical Effect of Surgical Castration Combined with Antiandrogen in the Treatment of Advanced Prostate Cancer
Endocrine therapy has a greater side effect, especially the use of androgen blocking therapy, will reduce the quality of life of patients in varying degrees, especially in patients with surgical castration, psychological impact is greater. This paper discusses the clinical effect of surgical castration combined with intermittent antiandrogens in the treatment of advanced prostate cancer. The patients in the operation group received oral administration of antiandrogens within one week, while the patients in the control group received luteinizing hormone releasing hormone analogue (LHRH-A) and antiandrogens. Serum PSA, testosterone, liver and kidney function, blood routine, bone scan and Pelvic MRI were measured during the treatment period and intermittence period, and the quality of life was scored before treatment, 6 months and 12 months after treatment. The results showed that all the patients were sensitive to endocrine therapy. The serum PSA of the patients in the operation group decreased to the lowest value after endocrine therapy (1.2 ± 0.4) months. The serum PSA of the 23 patients in the control group decreased to the lowest value after endocrine therapy (3.4 ± 0.7) months. The prostate volume of the two groups decreased significantly. The quality of life score showed that the patients' libido decreased, paroxysmal hot flashes, physical and mental state were significantly improved in the intermittent period (P < 0.01), and the remission of the control group was more obvious than that of the operation group (P < 0.05). Surgical castration combined with intermittent androgen is an effective method for the treatment of advanced prostate cancer, especially for the patients who have undergone castration, who are older or poor in economic tolerance.